About Us
Our Vision
Bonus BioGroup strives to become a global leader in Next-Generation Therapies in cell therapy and tissue engineering to improve human health
Our mission
Our mission is to help millions of people to live a better and longer life by merging innovative biological sciences and biomedical and biotechnology engineering.
2022
Planned launch of MesenCure global phase III trial and BonoFill™ phase II/III clinical trial in the US
2022
2021
Completed a successful multi-center phase II clinical trial for treating severe COVID patients with MesenCure.
2020
Launch of Phase I/II clinical trial testing MesenCure, an enhanced cell therapy, in severe COVID patients.
2020
2019
Granting Bonus BioGroup’s primary patents for the generation and usage of 3D cell-based bone implants.
2017
Launch of phase I/II clinical trial evaluating the safety and efficacy of BonoFill™ in orthopedic indications.
2017
2016
Successful first-in-human demonstration of the safety and efficacy of BonoFill™ and launch of phase I/II clinical trial testing 2nd generation BonoFill™ for maxillofacial bone regeneration.
2014
Launch of the first-in-human clinical trial with BonoFill™, an injectable bone graft for maxillofacial bone regeneration
2014
2013
Establishment of the world’s first live human bone graft manufacturing facility in Haifa, Israel
2008
Bonus* was founded by experts in tissue engineering and cell therapy led by Dr. Shai Meretzki, who pioneered the industrial development of mesenchymal cell therapies.
2008
Our Vision
Bonus BioGroup strives to become a global leader in Next-Generation Therapies in cell therapy and tissue engineering to improve human health
Our mission
Our mission is to help millions of people to live a better and longer life by merging innovative biological sciences and biomedical and biotechnology engineering.
2022
Planned launch of MesenCure global phase III trial and BonoFill™ phase II/III clinical trial in the US
2022
2021
Completed a successful multi-center phase II clinical trial for treating severe COVID patients with MesenCure.
2020
Launch of Phase I/II clinical trial testing MesenCure, an enhanced cell therapy, in severe COVID patients.
2020
2019
Granting Bonus BioGroup’s primary patents for the generation and usage of 3D cell-based bone implants.
2017
Launch of phase I/II clinical trial evaluating the safety and efficacy of BonoFill™ in orthopedic indications.
2017
2016
Successful first-in-human demonstration of the safety and efficacy of BonoFill™ and launch of phase I/II clinical trial testing 2nd generation BonoFill™ for maxillofacial bone regeneration.
2014
Launch of the first-in-human clinical trial with BonoFill™, an injectable bone graft for maxillofacial bone regeneration
2014
2013
Establishment of the world’s first live human bone graft manufacturing facility in Haifa, Israel
2008
Bonus* was founded by experts in tissue engineering and cell therapy led by Dr. Shai Meretzki, who pioneered the industrial development of mesenchymal cell therapies. <read more> *Bonus Therapeutics Ltd., a wholly-owned subsidiary of Bonus BioGroup Ltd.
2008
info@bonus-bio.com
+972 (0)73 206 7104
Matam Advanced Technology
